Resectable Osteosarcoma
1 clinical trials · Condition
◉ Watch Resectable Osteosarcoma
| Record | Firm | Date |
|---|---|---|
| Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma (NCT04751383) | National Cancer Institute (NCI) | 2021-08-31 |
Track Resectable Osteosarcoma automatically
Every clearance here is in the API, with alerts when new ones post.